Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 9/20 | 0.52 |
| ▸ | CA2 | P00918 | 9/20 | 0.52 |
| ▸ | CA9 | Q16790 | 8/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.50 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | STS | P08842 | 4/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9451267 | 0.85 | CA2 (0.61) | CA1CA2CA9STS | |
| SCHEMBL28100659 | 0.84 | HSD11B1 (0.51) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL27976599 | 0.83 | HSD11B1 (0.47) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL29382842 | 0.82 | HSD11B1 (0.50) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL235067 | 0.82 | HSD11B1 (0.50) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL2001002 | 0.80 | HSD11B1 (0.53) | CA1CA2HSD11B1HSD17B3TP53 | |
| Ammonia Solution, Strong SCHEMBL11405643 | 0.80 | HSD11B1 (0.49) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL9541027 | 0.80 | HSD11B1 (0.49) | CA1CA2CA9HSD11B1HSD17B3 | |
| SCHEMBL28814954 | 0.78 | HSD11B1 (0.51) | CA1CA2HSD11B1HSD17B3TP53 | |
| SCHEMBL31683755 | 0.78 | HSD11B1 (0.56) | CA1CA2HSD11B1HSD17B3TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-03 | — | — | US | disclosed |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2018-06-07 | — | — | US | disclosed |
| US-9895349-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | JANSSEN SCIENCES IRELAND US (IE) | 2018-02-20 | — | — | US | disclosed |
| EP-2981536-B1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | JANSSEN SCIENCES IRELAND UC (IE) | 2017-06-14 | — | — | EP | disclosed |
| EP-1667984-B1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME (GB) | 2011-05-18 | — | — | EP | disclosed |
| EP-1560580-B1 | SULFONAMIDES, SULFAMATES AND SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2011-01-12 | — | — | EP | disclosed |
| US-7514459-B2 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LTD. (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1551797-B1 | CYCLOHEXYL SULPHONE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME (GB) | 2007-02-21 | — | — | EP | disclosed |
| US-20060293373-A1 | Gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-28 | — | — | US | disclosed |
| US-7144910-B2 | Sulfonamides, sulfamates and sulfamides as gamma-secretase inhibitors | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-05 | — | — | US | disclosed |
| WO-2004039370-A1 | SULFONAMIDES, SULFAMATES AND SULFAMIDES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-05-13 | — | — | WO | disclosed |
| WO-2004031137-A1 | CYCLOHEXYL SULPHONE DERIVATIVES AS GAMMA-SECRETASE INHIBITORS | MERCK SHARP & DOHME LIMITED (GB) | 2004-04-15 | — | — | WO | disclosed |
| US-5268374-A | Containing both amide and hydroxy groups | ABBOTT LABORATORIES (US) | 1993-12-07 | — | — | US | disclosed |
| EP-0444156-A4 | METHOD FOR TREATING VASCULAR DISEASES | — | 1992-12-09 | — | — | EP | disclosed |
| EP-0437508-A4 | NON-PEPTIDE RENIN INHIBITORS | — | 1991-11-06 | — | — | EP | disclosed |
| EP-0444156-A1 | METHOD FOR TREATING VASCULAR DISEASES | ABBOTT LABORATORIES (US) | 1991-09-04 | — | — | EP | disclosed |
| EP-0437508-A1 | NON-PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1991-07-24 | — | — | EP | disclosed |
| WO-1990005531-A1 | METHOD FOR TREATING VASCULAR DISEASES | ABBOTT LABORATORIES (US) | 1990-05-31 | — | — | WO | disclosed |
| EP-0364804-A1 | Non-peptide renin inhibitors | ABBOTT LABORATORIES (US) | 1990-04-25 | — | — | EP | disclosed |
| WO-1990003971-A1 | NON-PEPTIDE RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1990-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293373-A1 | Gamma-secretase inhibitors | BACE1, BACE2, PSEN1 | CA1 976/4885CA2 3966/4885CA9 4400/4885 |
| US-10398677-B2 | N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis B | HCCS, PYGL, XDH | CA1 3239/4885CA2 1727/4885CA9 3344/4885 |
| US-20180153857-A1 | N-PHENYL-CARBOXAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B | HCCS, PYGL, XDH | CA1 3239/4885CA2 1727/4885CA9 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.